Down-regulation of miR-223 reverses epithelial-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells.
about
Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in CancerNew Insights into the Crossroads between EMT and Stemness in the Context of CancerNoncoding RNAs and pancreatic cancerΔNp63α and microRNAs: leveraging the epithelial-mesenchymal transitionMolecular Drivers of Pancreatic Cancer Pathogenesis: Looking Inward to Move Forward.Curcumin suppresses cell growth and invasion and induces apoptosis by down-regulation of Skp2 pathway in glioma cellsDeep sequencing identifies deregulation of microRNAs involved with vincristine drug-resistance of colon cancer cellsMiR-625-3p promotes cell migration and invasion via inhibition of SCAI in colorectal carcinoma cells.Noninvasive urinary miRNA biomarkers for early detection of pancreatic adenocarcinomaToward targeted therapy in chemotherapy-resistant pancreatic cancer with a smart triptolide nanomedicine.Synergistic reversal effect of epithelial-to-mesenchymal transition by miR-223 inhibitor and genistein in gemcitabine-resistant pancreatic cancer cells.miR-101 targeting ZFX suppresses tumor proliferation and metastasis by regulating the MAPK/Erk and Smad pathways in gallbladder carcinomaRottlerin exhibits anti-cancer effect through inactivation of S phase kinase-associated protein 2 in pancreatic cancer cells.Role of Notch signaling pathway in pancreatic cancer.MiRNA-145 increases therapeutic sensibility to gemcitabine treatment of pancreatic adenocarcinoma cells.Rottlerin exhibits antitumor activity via down-regulation of TAZ in non-small cell lung cancer.Suppression of CIP4/Par6 attenuates TGF-β1-induced epithelial-mesenchymal transition in NRK-52E cells.S-phase kinase-associated protein 2 promotes cell growth and motility in osteosarcoma cells.BRCA1 expression serves a role in vincristine resistance in colon cancer cells.MicroRNAs and Cancer Drug Resistance.MicroRNA in pancreatic cancer.Approaches for targeting cancer stem cells drug resistance.Epigenetics of epithelial-to-mesenchymal transition in pancreatic carcinoma.Epithelial-mesenchymal transition as a therapeutic target for overcoming chemoresistance in pancreatic cancer.Recent progress on the effects of microRNAs and natural products on tumor epithelial-mesenchymal transition.miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting METInhibition of Notch-1 pathway is involved in rottlerin-induced tumor suppressive function in nasopharyngeal carcinoma cells.Crosstalk between the Notch signaling pathway and non-coding RNAs in gastrointestinal cancers.miR-133b reverses cisplatin resistance by targeting GSTP1 in cisplatin-resistant lung cancer cells.Cell division cycle 20 promotes cell proliferation and invasion and inhibits apoptosis in osteosarcoma cells.Arsenic trioxide inhibits cell growth and motility via up-regulation of let-7a in breast cancer cells.MiR-26b reverses temozolomide resistance via targeting Wee1 in glioma cells.MiR-30a-5p confers cisplatin resistance by regulating IGF1R expression in melanoma cells.miR-1266 Contributes to Pancreatic Cancer Progression and Chemoresistance by the STAT3 and NF-κB Signaling Pathways.Clinical significance of miRNA - 106a in non-small cell lung cancer patients who received cisplatin combined with gemcitabine chemotherapy.Non-Coding RNAs and Resistance to Anticancer Drugs in Gastrointestinal Tumors.
P2860
Q26741846-9F2E3D5D-864F-49F2-9E32-2967FCEC9D2FQ26764831-E2713E1D-8922-49ED-8D6F-D89F29DB172AQ26774630-0E09F062-470D-4986-AC61-981B55BD7A68Q28077508-ED951D9A-8C5A-449C-A4C8-B79D3452EB87Q33624574-589AC679-0124-479C-B111-1A6C9FA2A14BQ36228504-7F9D9DC1-84AA-46FB-8B02-EA779C4526C0Q36261916-85E16A1A-3105-4334-9348-866D83E1EBB8Q36413914-CDCBCF49-90D7-4B08-84FF-9AF79CC28503Q36420185-90F95A87-582F-4FCA-9176-0D55C3C4B836Q36946804-77EF22BC-CA25-48CA-A396-F96980429200Q37077423-866BB26D-077A-43F3-9217-D55BAA2E03E6Q37225543-BD2D2BF6-7730-46B1-9C4D-1CEAA301CC0BQ37382511-09AE7D5B-F4C8-452E-87C0-78CEA3337964Q37679979-5CBB1705-C43D-4E5C-B5F0-4C1CABC59569Q37688623-024E3079-A96D-46DE-B740-38011FA46D9CQ37702621-EEF0C79B-0718-423C-A43A-CADD8A1ADEB6Q38604585-9B8279C2-3A1F-4E6F-9B0D-A3A84F089CB4Q38644806-357D4210-6F37-46E0-8373-C29F03CDF049Q38697693-93CC8690-A2FC-419F-8B33-9B62B21B21C4Q38748118-8172662A-AA5E-4485-B19C-2331F23285C3Q38850617-FE4CAB8D-5528-4658-B6CC-1DFC93516D02Q38971795-E9A0B4FD-2E2D-4C2F-9806-8FE6C16B3F6BQ39108676-EF8C37AA-F22D-4E19-AD0E-AAEE6AE372FDQ39112764-A4A1665B-D010-4D20-80B8-7C9E91021E1BQ39458257-47B93722-BAB1-46E5-8E48-3408AAA84AC1Q41134348-CD2512D7-3136-4009-8FE9-61CCFE70E8B3Q42365327-2442BBE9-4957-4E01-B200-8449CA64F1C6Q47101032-B0F5379F-4407-4BA1-8DBA-A1CB84187395Q48540173-86C42C0E-2B66-4468-944E-BD311536E757Q49584310-BB3BEC77-731C-4E70-8C57-84247CAD2FB4Q49584338-9D7712D4-BAE3-4E47-A9A8-CD3D703D0562Q50133239-4170DB9B-CD36-4539-9FC6-F3B078E1E5E5Q52720005-54F764CA-F6E7-4D28-B6D4-1CB1029C56A6Q55368106-E6F1164D-B36D-4B9F-A9AA-705A53117028Q55399368-16FA5A91-FF7C-4CA3-B5BD-7521B0CED8EEQ55403266-BB6E7776-7ABE-4F66-9BB5-AFB06A95E4AF
P2860
Down-regulation of miR-223 reverses epithelial-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Down-regulation of miR-223 rev ...... stant pancreatic cancer cells.
@ast
Down-regulation of miR-223 rev ...... stant pancreatic cancer cells.
@en
type
label
Down-regulation of miR-223 rev ...... stant pancreatic cancer cells.
@ast
Down-regulation of miR-223 rev ...... stant pancreatic cancer cells.
@en
prefLabel
Down-regulation of miR-223 rev ...... stant pancreatic cancer cells.
@ast
Down-regulation of miR-223 rev ...... stant pancreatic cancer cells.
@en
P2093
P2860
P356
P1433
P1476
Down-regulation of miR-223 rev ...... stant pancreatic cancer cells.
@en
P2093
Binbin Fang
Fanpeng Zeng
Haijie Pang
Long Cheng
P2860
P304
P356
10.18632/ONCOTARGET.2714
P407
P577
2015-01-01T00:00:00Z